1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

SBHMY
Sino Biopharmaceutical LimitedUS flagOther OTC
12.49
USD
- -
- -
11.13BMarket Cap
Sino Biopharmaceutical Limited
SBHMY
(Other OTC)

Recent

price

12.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.25
5.6
7.24
9.28
11.87
14.61
16.24
17.77
22.52
25.77
25.16
28.62
27.95
28.28
31.56
35.37
27
Revenue per Share
0.59
0.45
0.86
0.97
1.45
1.79
1.96
2.6
9.75
2.94
2.95
15.57
2.73
2.52
3.83
2.6
10.69
Basic EPS, GAAP
0.13
0.77
0.98
0.93
1.59
0.96
2.52
2.73
3.67
3.82
3.69
3.7
4.9
4.71
5.71
8.43
- -
Free Cash Flow per Basic Share
0.4
0.38
0.19
0.23
0.31
0.3
0.45
0.54
0.77
0.87
1.26
1
1.36
0.68
2.02
1.67
- -
Dividend per Share
1.94
1.83
2.26
2.88
3.85
5.14
6.6
0.2
0.3
0.3
0.44
25.03
25.22
25.97
28.09
28.18
0.44
Book Value per Share
4.34
4.52
5.47
6.63
8.19
10.18
12.48
14.75
15.77
19.09
22.77
38.38
38.69
38.06
43.42
38.92
31.19
Tangible Book Value per Share
819
836
834
834
834
834
834
834
927
941
940
938
931
926
915
900
939
Basic Weighted Avg Shares
3,482
4,680
6,036
7,737
9,898
12,184
13,543
14,819
20,889
24,234
23,647
26,861
26,026
26,199
28,866
31,834
25,353
Sales/Revenue/Turnover
26.79
16.39
18.49
17.8
18.43
19.55
20.38
22.01
20.68
21.45
18.2
16.21
21.05
23.23
21.94
21.67
19.82
Operating Margin (%)
73
110
144
175
207
296
317
343
1,176
1,446
1,655
993
1,047
1,074
1,321
1,212
- -
Depreciation Expense
483
375
717
810
1,210
1,489
1,637
2,171
9,046
2,762
2,771
14,608
2,544
2,332
3,500
2,343
10,038
Net Income, GAAP
20.98
16.72
17.71
16.59
15.71
15.47
14.83
12.92
6.09
15.86
13.41
10.54
13.36
14.74
9.34
23.46
10.95
Effective Tax Rate (%)
13.87
8
11.88
10.47
12.22
12.22
12.09
14.65
43.31
11.4
11.72
54.38
9.77
8.9
12.12
7.36
39.59
Profit Margin (%)
2,501
1,698
2,257
2,537
3,454
3,697
7,076
8,092
8,798
16,790
11,851
8,158
5,784
1,199
5,129
9,266
12,328
Working Capital
108
28
16
- -
1,030
257
1,679
2,210
555
7,926
12,628
5,532
4,258
1,373
2,080
7,651
11,807
LT Debt
3,666
3,866
4,658
5,646
7,051
8,742
10,678
12,611
17,779
20,561
22,420
37,729
37,944
38,170
42,774
42,086
31,109
Total Equity
22.55
16.35
20.94
21.62
21.22
21.12
19.24
18.88
21.59
17.15
11.23
8.94
9.27
10.03
11.02
9.41
8.82
Return on Invested Capital (%)
33.95
3.69
11.42
6.84
11.04
8.34
6.33
8.47
99.69
8.06
8.51
40.66
1.03
-0.03
1.99
-0.84
36.7
Return on Capital (%)
30.58
24.03
42.02
37.79
43.15
39.76
33.44
76.47
4,030.64
991.05
798.19
122.23
10.83
9.81
14.07
9.18
2,892.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
ST Debt
1,582
1,225
1,846
LT Borrowings
12,363
12,317
11,516
LT Finance Leases
265
264
291
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18,861
18,861
18,861
Market Capitalization
111,736
120,513
126,759

Working Capital

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
Total Current Assets
22,794
21,791
23,813
Cash, Cash Equivalents & STI
11,259
7,932
8,028
Accounts Receivable, Net
2,248
3,251
5,059
Inventories
1,880
1,813
1,732
Total Current Liabilities
10,944
10,358
11,485
Payables & Accruals
- -
- -
- -
ST Debt
1,582
1,225
1,846
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.58%
15.98%
-1.61%
Free Cash Flow
31.52%
18.44%
45.35%
Net Income, GAAP
64.34%
70.66%
-33.04%
Sales/Revenue/Turnover
10.68%
6.32%
10.28%
Total Cash Common Dividend
32.64%
27.45%
-18.62%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
26,199
2024
- -
- -
- -
- -
28,866
2025
- -
- -
- -
- -
31,834

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.52
2024
- -
- -
- -
- -
3.83
2025
- -
- -
- -
- -
2.6

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.68
2024
- -
- -
- -
- -
2.02
2025
- -
- -
- -
- -
1.67
Similar Companies
Advicenne S.A. (ADVIC.PA)
Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
Celcuity Inc. (CELC)
Alopexx, Inc. (ALPX)
Green Cross Cell Corporation (031390.KQ)
Versartis, Inc. (VSAR)
Business
Sino Biopharmaceutical Limited (HKEX: 1177; OTC: SBHMY) is a leading research-driven pharmaceutical company focused on the research, development, manufacture and marketing of innovative biopharmaceutical and chemical medicines across oncology, surgery/analgesia, hepatitis, respiratory system, cardio-cerebral vascular and other therapeutic areas. Founded in 1995 and headquartered in Hong Kong with principal operations in mainland China including facilities in Beijing, Lianyungang and Nanjing, the company operates primarily in China and pursues global expansion through partnerships and acquisitions. Its core products include oncology medicines such as Focus V (Anlotinib Hydrochloride) capsules, Annike (Penpulimab) injection, Qingkeshu (Abiraterone Acetate) tablets, Zewanxin (Lenvatinib Mesilate) capsules and Anxian (Lenalidomide) capsules; surgery/analgesia medicines such as Debaian (Flurbiprofen Cataplasms), Gaisanchun (Calcitriol) soft capsules and Chia Tai Jiuli (Glucosamine hydrochloride) tablets; hepatitis medicines including Tianqing Ganmei (Magnesium Isoglycyrrhizinate) injection, Runzhong (Entecavir) dispersible tablets and Tianqing Ganping (Diammonium Glycyrrhizinate) enteric-coated capsules; respiratory medicines such as Tianqing Suchang (Budesonide) suspension for inhalation and Tianqing Sule (Tiotropium Bromide) powder for inhalation; cardio-cerebral vascular medicines like Yilunping (Irbesartan and Hydrochlorothiazide) tablets and Tuotuo (Rosuvastatin Calcium) tablets; as well as others including Taibowei (Adalimumab) injection and Aisuping (Omeprazole) enteric-coated capsules. Oncology accounts for around 37% of revenue, with innovative products comprising 42% of total sales in recent periods. Recent developments include the July 2025 completion of invoX Pharma's $161 million acquisition of F-star Therapeutics, enhancing its bispecific antibody capabilities in immunotherapy following U.S. regulatory clearance; the July 2025 agreement to acquire the remaining 95% stake in LaNova Medicines for up to $951 million (net $501 million after cash), integrating advanced oncology assets like PD-1xVEGF bispecific LM-299 (licensed to Merck), GPRC5D ADC LM-305 (licensed to AstraZeneca), Claudin 18.2 ADC in phase 3 and CCR8 antibody in phase 2, bolstering antibody platforms in tumor microenvironment, ADCs and T-cell engagers; NMPA approval in February 2025 for Limaprost tablet (Kailitong) targeting lumbar spinal stenosis affecting over 30 million patients; CDE acceptance of clinical trial application for innovative Claudin18.2 ADC TQB2103; and plans to establish a Guangzhou innovation center as southern headquarters. The company maintains a robust R&D pipeline with over 40 oncology candidates and invests heavily in innovation, positioning it as a top player in China's pharmaceutical sector with products distributed domestically and internationally.

Company News

APIChat

  • reuters.com

    Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

  • forbes.com

    Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea

  • seekingalpha.com

    Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day